Citadel Advisors
ADAP

Citadel Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Citadel Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-137,700
Closed -$17.9K – 12522
2025
Q3 		$17.9K Buy
+137,700
New +$18.9K ﹤0.01% 12512
2025
Q2 		– Sell
-61,900
Closed -$12.2K – 12333
2025
Q1 		$12.2K Buy
61,900
+47,200
+321% +$24.4K ﹤0.01% 13456
2024
Q4 		$7.92K Sell
14,700
-13,400
-48% -$9.77K ﹤0.01% 13706
2024
Q3 		$26.7K Sell
28,100
-38,700
-58% -$43.9K ﹤0.01% 12541
2024
Q2 		$65.1K Buy
66,800
+24,000
+56% +$26.3K ﹤0.01% 11461
2024
Q1 		$67.6K Buy
+42,800
New +$51.7K ﹤0.01% 11861
2023
Q4 		– Sell
-400
Closed -$312 – 14178
2023
Q3 		$312 Sell
400
-5,775
-94% -$4.85K ﹤0.01% 14090
2023
Q2 		$5.71K Sell
6,175
-3,825
-38% -$4.56K ﹤0.01% 13477
2023
Q1 		$10.9K Sell
10,000
-1,100
-10% -$1.7K ﹤0.01% 13499
2022
Q4 		$16.2K Sell
11,100
-11,000
-50% -$17.8K ﹤0.01% 13288
2022
Q3 		$24K Sell
22,100
-36,500
-62% -$67.1K ﹤0.01% 11994
2022
Q2 		$100K Buy
58,600
+31,500
+116% +$54.1K ﹤0.01% 11410
2022
Q1 		$56K Sell
27,100
-27,900
-51% -$75.3K ﹤0.01% 12714
2021
Q4 		$206K Buy
55,000
+500
+0.9% +$2.28K ﹤0.01% 11783
2021
Q3 		$282K Sell
54,500
-32,900
-38% -$148K ﹤0.01% 11175
2021
Q2 		$372K Buy
87,400
+26,100
+43% +$127K ﹤0.01% 10747
2021
Q1 		$326K Buy
61,300
+49,300
+411% +$282K ﹤0.01% 10648
2020
Q4 		$65K Sell
12,000
-5,300
-31% -$28.8K ﹤0.01% 10458
2020
Q3 		$138K Buy
17,300
+5,300
+44% +$46.4K ﹤0.01% 9058
2020
Q2 		$120K Sell
12,000
-10,000
-45% -$62.8K ﹤0.01% 8885
2020
Q1 		$60K Buy
+22,000
New +$73K ﹤0.01% 8939
2019
Q1 		– Sell
-19,900
Closed -$114K – 9193
2018
Q4 		$114K Buy
19,900
+5,500
+38% +$40.6K ﹤0.01% 8192
2018
Q3 		$195K Sell
14,400
-600
-4% -$6.29K ﹤0.01% 8229
2018
Q2 		$178K Buy
15,000
+4,300
+40% +$53.6K ﹤0.01% 7975
2018
Q1 		$120K Buy
+10,700
New +$93.6K ﹤0.01% 7651

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citadel Advisors's ADAP Position: Q1 2025 in Review

Citadel Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 175,052 shares — an estimated $90.6K sold.

Citadel Advisors first reported a position in ADAP in Q2 2015 and held it in 29 quarters. The position peaked at $39M in Q3 2020. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • Citadel Advisors reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 175,052 Adaptimmune Therapeutics shares in Q1 2025, an estimated $90.6K.
  • Citadel Advisors first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 29 quarters.
  • Citadel Advisors's Adaptimmune Therapeutics position peaked at $39M in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.